Corvus Pharmaceuticals to Report Phase 1 Trial Results for Soquelitinib
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2024
0mins
Should l Buy CRVS?
Corvus Pharmaceuticals Inc. has seen its stock price surge by 45.96% in pre-market trading, reaching a 52-week high amid a challenging market environment where the Nasdaq-100 is down 1.79% and the S&P 500 is down 1.46%.
The significant price movement is attributed to the upcoming conference call on January 20, 2026, where the company will report results from cohort 4 of its Phase 1 trial evaluating soquelitinib for moderate to severe atopic dermatitis. This trial is expected to provide critical data that could influence future research and development efforts, showcasing the company's commitment to advancing its lead drug candidate in the immunotherapy sector.
The implications of this announcement are substantial, as positive trial results could enhance investor confidence and drive further interest in Corvus Pharmaceuticals' pipeline, particularly in light of the ongoing Phase 3 trial for relapsed/refractory PTCL. Investors are advised to monitor the outcomes closely, as they may significantly impact the company's market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRVS
Wall Street analysts forecast CRVS stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.070
Low
11.00
Averages
13.33
High
16.00
Current: 14.070
Low
11.00
Averages
13.33
High
16.00
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CORVUS PHARMACEUTICALS: OPPENHEIMER INCREASES TARGET PRICE TO $33, UP FROM $32
Company Overview: Corvus Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for cancer treatment.
Stock Price Update: The company has raised its price target from $32 to $33, indicating a positive outlook for its stock performance.
See More
Corvus (CRVS) Q4 2025 Earnings Call Transcript
See More
Corvus Pharmaceuticals Q4 2025 Earnings Call Insights
- Increased R&D Expenses: Corvus reported $9.9 million in R&D expenses for Q4 2025, driven by higher clinical trial and manufacturing costs for soquelitinib, alongside rising personnel costs, which exerted pressure on the company's financials.
- Improved Cash Position: As of December 31, 2025, Corvus had cash, cash equivalents, and marketable securities totaling $56.8 million, up from $52 million in 2024, indicating enhanced cash flow post-financing, expected to support operations into Q2 2028.
- Significant Clinical Progress: CEO Richard Miller highlighted soquelitinib's potential in atopic dermatitis and T-cell lymphoma, particularly noting a 72% mean reduction in EASI scores in the Phase I atopic dermatitis trial, demonstrating significant efficacy that could strengthen future market positioning.
- Optimistic Future Outlook: The company plans to initiate Phase II trials for hidradenitis suppurativa and asthma in 2026, with Phase II atopic dermatitis data expected in mid-2027, reflecting strong confidence in new therapies and positive market prospects.
See More
Corvus Pharmaceuticals Q4 Earnings Miss Expectations
- Earnings Report: Corvus Pharmaceuticals reported a Q4 GAAP EPS of -$0.15, missing expectations by $0.02, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Reserves Increase: As of December 31, 2025, Corvus had cash, cash equivalents, and marketable securities totaling $56.8 million, up from $52.0 million in 2024, reflecting improved financial management.
- Financing Progress: On January 23, 2026, Corvus completed a financing round that yielded approximately $189.4 million in net proceeds, which will provide crucial support for future operations, although this amount is not reflected in the current report.
- Operational Funding Outlook: Based on current plans, Corvus expects its cash to fund operations into the second quarter of 2028, providing assurance for the company's future financial stability, although market conditions will still need to be monitored.
See More
Corvus Pharmaceuticals Set to Announce Q4 Earnings on March 11
- Earnings Announcement: Corvus Pharmaceuticals is set to release its Q4 2023 earnings report on March 11 after market close, with a consensus EPS estimate of -$0.13, reflecting a significant 172.2% year-over-year decline, indicating ongoing profitability challenges.
- Revenue Expectations: Analysts project Corvus Pharmaceuticals' revenue to be $0, suggesting the company may struggle to generate sales in the current quarter, highlighting challenges in product market acceptance.
- EPS Forecast Changes: Over the past three months, there has been one upward revision and no downward adjustments to EPS estimates, indicating cautious optimism in the market regarding the company's future performance, although actual earnings results will be critical.
- Stock Performance: Corvus Pharmaceuticals' stock recently rose by 5% as it priced a $175 million stock offering at $22.15 per share, reflecting positive market sentiment towards its financing activities, but also potentially signaling concerns about future capital needs.
See More
Analysis of Corvus Pharmaceuticals Put Selling
- Options Selling Risk: Selling puts on Corvus Pharmaceuticals does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, which only benefits them if the stock declines by 62.9% to trigger the $8 strike price.
- Yield Analysis: The only upside for the put seller comes from the premium collected, yielding an annualized return of 10.2%, but this must be weighed against potential market risks and stock price volatility.
- Volatility Assessment: Corvus Pharmaceuticals has a trailing twelve-month volatility of 122%, based on the last 250 trading days, indicating significant price fluctuations and a relatively high risk for selling options.
- Market Price Comparison: With the current stock price at $21.47, selling puts at an $8 strike could lead to losses under adverse market conditions, necessitating careful evaluation of the risk-reward balance by investors.
See More
CORVUS PHARMACEUTICALS: OPPENHEIMER INCREASES TARGET PRICE TO $33, UP FROM $32
Company Overview: Corvus Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for cancer treatment.
Stock Price Update: The company has raised its price target from $32 to $33, indicating a positive outlook for its stock performance.
See More
Corvus (CRVS) Q4 2025 Earnings Call Transcript
See More
Corvus Pharmaceuticals Q4 2025 Earnings Call Insights
- Increased R&D Expenses: Corvus reported $9.9 million in R&D expenses for Q4 2025, driven by higher clinical trial and manufacturing costs for soquelitinib, alongside rising personnel costs, which exerted pressure on the company's financials.
- Improved Cash Position: As of December 31, 2025, Corvus had cash, cash equivalents, and marketable securities totaling $56.8 million, up from $52 million in 2024, indicating enhanced cash flow post-financing, expected to support operations into Q2 2028.
- Significant Clinical Progress: CEO Richard Miller highlighted soquelitinib's potential in atopic dermatitis and T-cell lymphoma, particularly noting a 72% mean reduction in EASI scores in the Phase I atopic dermatitis trial, demonstrating significant efficacy that could strengthen future market positioning.
- Optimistic Future Outlook: The company plans to initiate Phase II trials for hidradenitis suppurativa and asthma in 2026, with Phase II atopic dermatitis data expected in mid-2027, reflecting strong confidence in new therapies and positive market prospects.
See More
Corvus Pharmaceuticals Q4 Earnings Miss Expectations
- Earnings Report: Corvus Pharmaceuticals reported a Q4 GAAP EPS of -$0.15, missing expectations by $0.02, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Reserves Increase: As of December 31, 2025, Corvus had cash, cash equivalents, and marketable securities totaling $56.8 million, up from $52.0 million in 2024, reflecting improved financial management.
- Financing Progress: On January 23, 2026, Corvus completed a financing round that yielded approximately $189.4 million in net proceeds, which will provide crucial support for future operations, although this amount is not reflected in the current report.
- Operational Funding Outlook: Based on current plans, Corvus expects its cash to fund operations into the second quarter of 2028, providing assurance for the company's future financial stability, although market conditions will still need to be monitored.
See More
Corvus Pharmaceuticals Set to Announce Q4 Earnings on March 11
- Earnings Announcement: Corvus Pharmaceuticals is set to release its Q4 2023 earnings report on March 11 after market close, with a consensus EPS estimate of -$0.13, reflecting a significant 172.2% year-over-year decline, indicating ongoing profitability challenges.
- Revenue Expectations: Analysts project Corvus Pharmaceuticals' revenue to be $0, suggesting the company may struggle to generate sales in the current quarter, highlighting challenges in product market acceptance.
- EPS Forecast Changes: Over the past three months, there has been one upward revision and no downward adjustments to EPS estimates, indicating cautious optimism in the market regarding the company's future performance, although actual earnings results will be critical.
- Stock Performance: Corvus Pharmaceuticals' stock recently rose by 5% as it priced a $175 million stock offering at $22.15 per share, reflecting positive market sentiment towards its financing activities, but also potentially signaling concerns about future capital needs.
See More
Analysis of Corvus Pharmaceuticals Put Selling
- Options Selling Risk: Selling puts on Corvus Pharmaceuticals does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, which only benefits them if the stock declines by 62.9% to trigger the $8 strike price.
- Yield Analysis: The only upside for the put seller comes from the premium collected, yielding an annualized return of 10.2%, but this must be weighed against potential market risks and stock price volatility.
- Volatility Assessment: Corvus Pharmaceuticals has a trailing twelve-month volatility of 122%, based on the last 250 trading days, indicating significant price fluctuations and a relatively high risk for selling options.
- Market Price Comparison: With the current stock price at $21.47, selling puts at an $8 strike could lead to losses under adverse market conditions, necessitating careful evaluation of the risk-reward balance by investors.
See More
